Who are Extract of Agaricus blazei Murill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): histamine dihydrochloride and IL-2, Single Dose of Hydroxychloroquine, BG00012 (DMF), Interferon-Alpha, PAD combination, Iguratimod Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/extract-of-agaricus-blazei-murill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Extract of Agaricus blazei Murill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extract of Agaricus blazei Murill (Extract of Agaricus blazei Murill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator; natural product extract. Area: Oncology; Immunology.

phase 3 Immunomodulator; natural product extract Pattern recognition receptors (Dectin-1, TLR); macrophage and NK cell activation Oncology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Extract of Agaricus blazei Murill (Extract of Agaricus blazei Murill) — ECbiotech Taiwan. Agaricus blazei Murill extract enhances immune function through polysaccharide and beta-glucan components that activate macrophages, natural killer cells, and other innate immune cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Extract of Agaricus blazei Murill TARGET	Extract of Agaricus blazei Murill	ECbiotech Taiwan	phase 3	Immunomodulator; natural product extract	Pattern recognition receptors (Dectin-1, TLR); macrophage and NK cell activation
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
Single Dose of Hydroxychloroquine	Single Dose of Hydroxychloroquine	Shahid Beheshti University of Medical Sciences	marketed	Antimalarial immunomodulator	Toll-like receptors (TLR); lysosomal pH modulation
BG00012 (DMF)	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
Iguratimod Tablets	Iguratimod Tablets	Wangjing Hospital, China Academy of Chinese Medical Sciences	marketed	Small-molecule immunomodulator	NF-κB pathway; multiple cytokine targets

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator; natural product extract class)

ECbiotech Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Extract of Agaricus blazei Murill — Competitive Intelligence Brief. https://druglandscape.com/ci/extract-of-agaricus-blazei-murill. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab